This article was originally published July 24.
By Julia Karow
Roche said last week that its Applied Science business, which includes 454 Life Sciences and Roche NimbleGen, posted CHF 403 million ($376 million) in sales for the first half of 2009, an 8 percent gain over the same period last year.
The 454 GS FLX platform and microarrays "continue to drive growth" of the business, "delivering robust double-digit sales increases," according to Roche. Sales of the xCELLigence cell analysis system "also contributed significantly to growth" of the Applied Science business.
Roche's diagnostics division, which houses Roche Applied Science, reported sales of CHF 4.9 billion during the first six months of 2009, growth of 3 percent over the comparable period of 2008 that was "driven primarily by Professional Diagnostics and Tissue Diagnostics."
The Applied Science business contributed 8 percent of the division's sales.
Total sales for the Roche group for the first half of the year — including both the pharmaceuticals and diagnostics divisions — were CHF 24 billion, up 9 percent from last year.
Roche's net income totaled CHF 4.1 billion, down 29 percent compared to last year due to "exceptional operating expenses" related to the purchase and integration of Genentech, which Roche acquired earlier this year.